Transplant Outcomes for Primary Immunodeficiency Disease

Angela R. Smith, Thomas G. Gross, K. Scott Baker

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Primary immune deficiencies (PIDs) are rare diseases, and most are lethal without appropriate intervention. Hematopoietic cell transplantation (HCT) can cure the majority of patients, but most lack a suitable matched related donor. Alternative donor stem cells (mismatched related donor bone marrow, unrelated donor bone marrow, and unrelated donor umbilical cord blood [UCB]) are therefore frequently required. Published data comparing outcomes after alternative donor transplant for PID are scarce. The outcomes and potential advantage and disadvantages of each alternative stem cell source are discussed in this chapter. Although there are insufficient prospective data to make meaningful comparisons between the alternative stem cell sources, the results presented here demonstrate clearly that the use of UCB transplantation for PID is a viable option and may be advantageous in many situations.

Original languageEnglish (US)
Pages (from-to)79-85
Number of pages7
JournalSeminars in hematology
Issue number1
StatePublished - Jan 2010


Dive into the research topics of 'Transplant Outcomes for Primary Immunodeficiency Disease'. Together they form a unique fingerprint.

Cite this